01.12.24 -- mRNA Vaccine Platforms, Allogeneic 2024 Outlook, Overcoming CAR-T Limitations, and more.

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

Vittoria Biotherapeutics’ CEO shares the company's mission to expand the applications for CAR-based therapeutics by employing novel cell engineering and gene editing technologies.

A first-time attendee of Meeting on the Mesa discusses his experience and delves into the cell therapy used to treat corneal endothelial disease.

Kristin Yarema, Ph.D., CEO, Poseida Therapeutics, discusses four of the biggest challenges the CGT sector faces when it comes to the development of off-the-shelf therapies, plus shares how 2024 might see some real progress in allogeneic therapies. 

Combined Therapeutics president and CEO, Dr. Romain Micol, is operating his company in a very noisy space, where hundreds of new biotechs have popped up on the coattails of a COVID-driven renewal of interest in mRNA vaccines. Micol recognizes that noise and the competition it brings for capital and mindshare.

During his leadership of the President's Emergency Plan for AIDS Relief during the George W. Bush administration, Dr. Mark Dybul, MD, shepherded programs credited with saving over 25 million lives. Here, Dybul, CEO at Renovaro BioSciences, gets introspective on leadership forged in the fires of public service and battle-tested in the private sector.

Join us as we welcome two extraordinary guests — Dr. Neela Patel, a molecular biologist-turned-chief business officer, and Dr. John Mulligan, an academic-turned-founder of newly formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum's transition from its predecessor.

Here we take a trip to the land down under to visit with Dr. Sam Costello, managing director and co-founder at Adelaide, Australia-based BiomeBank. Learn about the unique path BiomeBank took to gain the first donor-derived microbiome therapeutic approval of its kind.

Fina Biosolutions' Dr. Andrew Lees recently signed on with Scorpius BioManufacturing to support his company's growth plan. Lees sits down with Scorpius’ VP of commercial operations, Steve Lavezoli, for a frank conversation on the ups, downs, and expectations of a biotech + CDMO relationship.